Financial Results - Globus Medical, Inc. reported preliminary unaudited net sales results for the fiscal year ended December 31, 2025[5] - The company provided preliminary guidance for certain financial measures for the fiscal year ending December 31, 2026[5] Press Release - The press release regarding these results was issued on January 7, 2026[5]

Industry Overview - The MedTech sector is navigating a global economy characterized by slowing growth, moderating inflation, and heightened geopolitical uncertainty, impacting healthcare spending and capital allocation decisions [1][2] - Despite challenges such as higher input costs and labor shortages, demand for advanced medical technologies remains steady due to the sector's essential nature and long-term innovation cycle [1][2] Economic Outlook - The IMF forecasts gradual deceleration of global growth through 2026, with advanced economies growing slower than emerging markets, while global inflation is expected to ease unevenly across regions [2] - Slower economic growth may constrain healthcare budgets, but moderating inflation and improved financial conditions could alleviate cost pressures and stabilize procurement trends [2][3] Future Projections - By 2026, the MedTech sector is anticipated to benefit from a more stable macro environment if inflation continues to decline and financing conditions remain favorable [3] - Demand is expected to favor technologies that enhance efficiency, outpatient care, and automation, positioning strong MedTech companies for better performance in a slower-growth economy [3] Investment Considerations - Investors may need to reassess MedTech companies that have seen significant gains but could face challenges in 2026 due to selective hospital spending and increased competition [4][9] - Companies like Globus Medical, TransMedics, and Hims & Hers have experienced strong growth driven by innovation, but sustaining this momentum may be difficult as macro conditions normalize [4][8][9] Company Highlights - **Globus Medical (GMED)**: Reported solid growth in Q3 2025, with a projected EPS and revenue increase of 3.9% and 7.9% respectively for 2026. The stock gained 3.8% over the past year [10][11] - **TransMedics (TMDX)**: Announced strong Q3 2025 results and a strategic collaboration for organ transportation. Expected EPS and revenue growth of 2.4% and 20.4% respectively for 2026. The stock surged 101.4% over the past year [12][14] - **Hims & Hers (HIMS)**: Reported strong Q3 2025 results with growth in subscribers and revenue. Projected EPS and revenue growth of 22.3% and 17.6% respectively for 2026. The stock increased by 32.6% over the past year [15][18]

Core Viewpoint - Globus Medical, Inc. (GMED) is showing potential as a strong stock pick due to a recent "golden cross" event, indicating a bullish trend reversal [1][2]. Technical Indicators - A "golden cross" occurs when a stock's short-term moving average (50-day) crosses above its long-term moving average (200-day), suggesting a bullish breakout is likely [2]. - The golden cross pattern consists of three stages: a downtrend followed by a crossover of moving averages, and finally an upward price movement [3]. Performance Metrics - Over the past four weeks, GMED has experienced a significant price increase of 38.1% [4]. - GMED currently holds a 1 (Strong Buy) rating on the Zacks Rank, indicating strong potential for further price appreciation [4]. Earnings Outlook - The earnings outlook for GMED is positive, with four upward revisions in earnings estimates over the past 60 days, and no downward revisions [4]. - The Zacks Consensus Estimate for GMED has also increased, reinforcing the bullish sentiment around the stock [4]. Investment Consideration - Given the technical indicators and positive earnings revisions, GMED should be considered for inclusion on investors' watchlists [6].

Core Viewpoint - Growth investors seek stocks with above-average financial growth, but identifying such stocks can be challenging due to associated risks and volatility [1] Group 1: Company Overview - Globus Medical (GMED) is highlighted as a recommended growth stock with a favorable Growth Score and a top Zacks Rank [2] - The company has a historical EPS growth rate of 15.9%, with projected EPS growth of 18.2% this year, surpassing the industry average of 18.1% [5] Group 2: Financial Metrics - Cash flow growth for Globus Medical is currently at 86.1%, significantly higher than the industry average of -2.4% [6] - The company's annualized cash flow growth rate over the past 3-5 years is 32.6%, compared to the industry average of 6.3% [7] Group 3: Earnings Estimates - There has been a positive trend in earnings estimate revisions for Globus Medical, with the Zacks Consensus Estimate for the current year increasing by 18% over the past month [8] - The combination of a Zacks Rank 1 and a Growth Score of A positions Globus Medical as a potential outperformer for growth investors [10]

Group 1 - The article discusses the investment potential of Globus Medical (GMED) after a challenging first quarter earnings report, suggesting that the stock deserves renewed backing [1] - The investment group "Value In Corporate Events" focuses on identifying opportunities in major corporate events such as earnings reports, M&A, and IPOs, providing coverage of 10 significant events monthly [1] - The author emphasizes a long position in GMED, indicating confidence in the company's future performance despite previous market pressures [2]

Core Insights - The cannabis sector is attracting investor interest due to growth opportunities despite market volatility, with marijuana penny stocks showing potential for significant upside as conditions improve [1][2] Industry Overview - The cannabis industry is adapting to changing consumer demands, competitive state markets, and evolving regulations, with a focus on financial discipline and strategic progress [2] - State-level expansion continues to support gradual industry growth, even amidst uncertainty regarding federal reform [2] Company Highlights - **Glass House Brands Inc. (GLASF)**: Focuses on large-scale greenhouse cultivation and retail operations in California, emphasizing cost reduction and brand recognition through strategic acquisitions and new store openings [4][7] - **Ascend Wellness Holdings, Inc. (AAWH)**: Operates across multiple states with a diverse product range, balancing pricing pressures and opportunities through geographic diversification and improved customer experiences [8] - **Planet 13 Holdings Inc. (PLNH)**: Known for its experience-based retail model, particularly in Las Vegas, and is expanding into new states while focusing on branded consumer products and operational efficiency [10][12] Financial Performance - **Glass House Brands**: Revenue growth driven by increased production and improved gross margins, with a positive trend in operating income as the company scales production [7] - **Ascend Wellness Holdings**: Revenue growth supported by wholesale and retail expansion, though still facing net losses due to debt and operating expenses; improving margins indicate operational progress [8] - **Planet 13 Holdings**: Modest revenue growth from store expansion, facing pressure on gross profit margins due to operating expenses, but showing progress in reducing overhead costs [12]

Core Insights - Globus Medical Inc. (NYSE:GMED) experienced a significant stock price increase of 38.9% week-on-week, driven by positive analyst ratings and strong third-quarter earnings performance [1] Analyst Ratings and Price Targets - BofA Securities upgraded Globus Medical to a "buy" recommendation from a "neutral" rating, setting a new price target of $91, representing a 47% upside from the previous closing price of $61.71 [2] - Wells Fargo also raised its price target for the company to $79 from $66, reflecting positive sentiment following the earnings report [3] Earnings Performance - In the third quarter, Globus Medical reported a net income increase of 129%, reaching $118.97 million compared to $51.84 million in the same period last year [3] - The company's net sales grew by 22.9%, totaling $769 million, up from $625.7 million year-on-year [3] Revenue Guidance - For the full year, Globus Medical raised its revenue guidance to a range of $2.86 billion to $2.9 billion, which is an increase from the previous lower end of $2.80 billion [4] Company Outlook - The President and CEO of Globus Medical expressed satisfaction with the company's results and emphasized a focus on consistent organic growth through innovation and execution [5]

Core Insights - Shares of the medical technology company are experiencing their largest same-day percentage increase on record [1] Company Summary - The medical technology company is witnessing a significant surge in its stock price, indicating strong market performance and investor confidence [1]

Core Insights - Globus Medical reported revenue of $769.05 million for the quarter ended September 2025, reflecting a year-over-year increase of 22.9% [1] - The company's EPS was $1.18, up from $0.83 in the same quarter last year, indicating a significant improvement [1] - The reported revenue exceeded the Zacks Consensus Estimate of $733.45 million by 4.85%, while the EPS surpassed the consensus estimate of $0.79 by 49.37% [1] Revenue Breakdown - International revenue reached $151.42 million, exceeding the average estimate of $144.37 million by analysts, marking a 16.6% increase year-over-year [4] - U.S. revenue was reported at $617.63 million, surpassing the average estimate of $589.84 million, with a year-over-year growth of 24.6% [4] - Net sales in the Enabling Technologies category were $28.04 million, below the average estimate of $40.23 million, representing a decline of 26.8% year-over-year [4] - Musculoskeletal Solutions generated $741.01 million in net sales, exceeding the average estimate of $693.98 million, with a year-over-year increase of 26.2% [4] Stock Performance - Shares of Globus Medical have returned +1.8% over the past month, compared to a +1.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Viewpoint - Globus Medical reported quarterly earnings of $1.18 per share, significantly exceeding the Zacks Consensus Estimate of $0.79 per share, marking an earnings surprise of +49.37% [1][2] Financial Performance - The company achieved revenues of $769.05 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 4.85% and showing an increase from $625.71 million year-over-year [2] - Over the last four quarters, Globus Medical has exceeded consensus EPS estimates three times and has also topped revenue estimates three times [2] Stock Performance - Globus Medical shares have declined approximately 25.6% since the beginning of the year, contrasting with the S&P 500's gain of 15.6% [3] - The current Zacks Rank for Globus Medical is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is $0.89, with expected revenues of $770.15 million, and for the current fiscal year, the estimate is $3.21 on $2.85 billion in revenues [7] - The trend of estimate revisions for Globus Medical was mixed prior to the earnings release, which may change following the recent results [6] Industry Context - The Medical - Instruments industry, to which Globus Medical belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]